Services & Links - Our Commitment to Growth Hormone Therapy

Our commitment to GH therapy

- Celebrating 20 years of Norditropin®

1988	Norditropin® approved in several European countries and Japan for GHD in children and in Denmark for Turner syndrome
1990	Nordiject® launched - a pen system for injection of growth hormone
1995	Norditropin® approved in USA
1995-6	Norditropin® approved for GHD in adults (GHDA) in Europe
1996	Norditropin® approved for chronic renal disease in Europe
1997	Norditropin® launched in USA Norditropin® approved for skeletal dysplasia in Japan
1999	Norditropin® SimpleXx® approved in EU and launched in several EU countries
2000	Norditropin® SimpleXx®, NordiPen®, and NordiPenMate® launched in the rest of Europe, Japan, and USA
2002-3	NordiNet® launched - an electronic data capturing system to facilitate observational studies, clinical research, and patient management
2003	Norditropin® SimpleXx® approved in EU for treatment of short children born small for gestational age (SGA), and launched from July 2003 and onwards Norditropin® NordiFlex® approved and launched in EU
2004	Norditropin® NordiFlex® approved and launched in Japan and USA Norditropin® SimpleXx® approved and launched in USA for GHD in adults (GHDA)
2005	NordiNet® International Outcome Study (IOS) launched - an observational long-term study on Norditropin® efficacy and safety
2006	NordiFlex PenMate® approved and launched in EU
2007	Norditropin® approved for treatment of children with short stature associated with Noonan syndrome in USA and launched in July Norditropin® approved for Turner syndrome in USA NordiFlex PenMate® approved and launched in USA NordiNet® International Outcome Study (IOS) reached 5000 patients
2008	Norditropin® launched in USA for Turner syndrome NordiFlex PenMate® approved and launched in Japan